Sales expected to explode for word respiratory market
NEW YORK - The use of prescription respiratory drugs is expected to pass $4 billion in sales by 2010.
According to a study released last week by Kalorama Information, 2005 revenues for respiratory medications reached more than $32 billion. New delivery methods, improved product performance, and an increasing incidence combined with an aging population have driven growth.
While there have been setbacks, such as patent losses, increasing drug resistance issues, and the burden of mandatory post-approval drug studies, among others, the potential for new drugs are keeping the focus of the industry on championing the unmet needs of respiratory sufferers.
"Increased understanding of respiratory disease processes coupled with advancements in drug delivery technology are making it possible for those with even the most acute respiratory ailments to find relief and improve the quality and longevity of their lives," stated Mary Anne Crandall, the report's author. "For example, scientists have discovered a drug that makes damaged lungs regrow--raising hopes of a cure for emphysema."
The study examines the global market for anti-inflammatories and inhaled corticosteroids; mast stabilizers, leukotriene modifiers, and other biologics; antihistamines, decongestants, and antitussives; brochodilators; lung fluid replacement and mucokinetic agents; and other drugs used to treat and manage symptoms in a wide range of respiratory illnesses.